相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
- 库存:
货期:询盘
- 供应商:
MedChemExpress LLC
- 规格:
询盘
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
ARQ 069
CAS No. : 1314021-57-2
MCE 国际站:ARQ 069
产品活性:ARQ 069 是 ARQ 523 的类似物,以对映体特异的方式抑制 FGFR 活性。ARQ 069 靶向非磷酸化,非活性形式的 FGFR1/FGFR2 激酶,IC50 分别为 0.84 μM 和 1.23 μM。ARQ 069 通过非 ATP 竞争的方式抑制 FGFR1/FGFR2 自磷酸化,IC50 分别为 2.8 μM 和 1.9 μM。
研究领域:Protein Tyrosine Kinase/RTK
作用靶点:FGFR
In Vitro: ARQ 069 (3.8-60 μM; for 2 hours) reduces the degree of phosphorylation of FGFR (predominantly FGFR2) in a concentration-dependent manner, without decreasing β-actin.
ARQ 069 shows an affinity for FGFR2 of 5.2 μM.
ARQ 069 inhibits FGFR phosphorylation in Kato III cells with an IC50 of 9.7 μM.
ARQ 069 targets the inactive forms of FGFR1 and FGFR2 kinases and inhibits their enzymatic activity. When ARQ 069 is preincubated with either phosphorylated FGFR1 or FGFR2, the potency of ARQ 069 in inhibiting Pyk2 phosphorylation is markedly reduced, with IC50 values determined to be greater than 30 and 24.8 μM for FGFR1 and FGFR2, respectively. ARQ 069 exhibits at least a 20-fold preference for binding to the unphosphorylated, inactive forms of FGFR1 and FGFR2.
ARQ 068 is the R-enantiomer, and ARQ 069 is the S-enantiomer.
相关产品:Lenvatinib | Regorafenib | Nintedanib | Ponatinib | Erdafitinib | Infigratinib | Pemigatinib | Pazopanib | Futibatinib | Fexagratinib | PD173074 | Heparan Sulfate | Formononetin | SU 5402 | Masitinib | Dovitinib | KW-2449 | Ferulic acid | Fisogatinib | Roblitinib | Gandotinib | BLU9931 | Triamcinolone acetonide | LY2874455 | PD-166866 | Sulfatinib | SM1-71
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Oxidative Stress and Beta Cell Dysfunction
, Diabetes 44:1176–1179, 1995), implicates free radicals as important effectors in T1D pathogenesis (Eizirik D et al., Nat Rev Endocrinol 5:219–226, 2009; Hanafusa T and Imagawa A, Ann NY Acad Sci 1150:297–299, 2008; Eisenbarth GS and Jeffrey J, Arq Bras
ν P(双侧)0.05 0.01 0.001 ν 0.05 0.01 0.001 P(单侧)0.025 0.005 0.0005 0.025 0.005 0.0005 1 12.706 63.657 636.618 21 2.080 2.831 3.819 2 4.303 9.925 31.598 22 2.072 2.819 3.792 3 3.182 5.841 12.924 23 2.069 2.807 3.767 4 2.776 4.604 8.610 24 2.064
A23(9) B16 B57(17) Cw9(w3) Dw10 DR8 DQ19(3) A24(9) B17 B54(17) Cw1(w3) Dw11(w7) DR9 A2403(9) B18 B
技术资料暂无技术资料 索取技术资料














